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Introduction
Erdheim-Chester disease (ECD) is a rare non-Langer-
hans systemic histiocytosis of unknown origin. ECD is
characterized by bilateral and symmetric sclerosis of the
metaphyseal regions of the long bones and infiltration in
other organs. Histopathologically, ECD is characterized
by a mononuclear infiltrate of foamy histiocytes.
Aim of the study
To assess the role of pro-inflammatory cytokines in the
physiopathology of the disease and efficacy of IL-1
blockade in treatment of pediatric ECD.
Patient
A 10 year-old girl with visceral and bone involvement
after failure of IFN-a treatment.
Methods
PBMC were isolated by Ficoll-Paque from whole blood,
cultured in RPMI and stimulated with LPS. IL-1, 6 and
TNF-a were measured in supernatant and in blood by
ELISA. Patient’s data were compared with 15 healthy
controls.
Result
The patient was followed for three years for daily fever
40°C, hepato-splenomegaly, bone pain of the lower
limbs and growth retardation. ESR (105mm/h) and C-
reactive protein level (CRP=97mg/l) were high. Bone X
ray found multiple osteolytic and osteosclerotic lesions
in femurs, tibia, and pelvis. Whole-body MRI showed
hyperintensity of the skeletal bone marrow in T2-
weighted images and retroperitoneal infiltration. Bone
biopsies confirmed ECD. The patient received 3x10
6
units of IFN-a2a thrice weekly. All symptoms disap-
peared, ESR and CRP normalized after 4 months. The
whole-body MRI showed regression of retroperitoneal
infiltration, and improvement of bone marrow intensity.
At month 10, the patient experienced a relapse. Serum
IL-6 drastically increased 174 pg/ml (N: 0-8.6) but not
IL-1 and TNF-a. The patient’sI L - 6 ,I L - 1 b and TNF-a
measurement from supernatant of PBMC culture
showed respectively increased levels compared to con-
trol, before (71.8ng/ml, 1290pg/ml, 980pg/ml vs 3±1.1,
32±8.9, 174±99) and after stimulation (155.9ng/ml,
3800pg/ml, 1250pg/ml vs 90±11, 3770±506, 1433±196).
The patient was then treated with Anakinra, an IL-1
receptor antagonist at 2mg/kg/day. In one week, fever,
bone pain resolved, ESR and CRP normalized. The child
gained 8 kg weight and 6 cm height in 10-month treat-
ment. MRI at month 7 showed stability of bone lesion
and retroperitoneal infiltration. No side effect was
notified.
Discussion
Patient’s PBMC secreted high amount of IL1 and IL-6 at
basal level which increased notably afer stimulation.
This may participate in the patho-physiology of ECD.
Conclusion
Our study supports a central role of the IL-1 network,
which seemed to be overstimulated. Its specific blockade
could be safely used in pediatric ECD. But we cannot
confirm that this could cure this severe disease.
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